Enforcement Briefing, week of Oct 4, 2026

On September 18, DOJ announced agreements resolving investigations into NYU Langone Hospitals and the University of Pittsburgh Medical Center concerning potential violations of federal law in their provision of gender-affirming care to minors. The announced commitments cover puberty blockers, cross-sex hormones and surgical procedures for minors. NYU agreed to pay $8.5 million and UPMC $950,000. These are the terms DOJ reported for the two organizations, rather than a court ruling that imposes the same service restrictions on other hospitals. Both systems expressly denied the allegations, and DOJ stated that liability had not been determined.

The resolutions sit within a wider DOJ investigation examining potential violations of the Food, Drug, and Cosmetic Act, the False Claims Act and other federal healthcare laws. The release identifies alleged use of false diagnosis codes to obtain payment from federal programs and private insurers as one billing concern under investigation. DOJ also credited both systems for significant cooperation, including ongoing cooperation concerning other entities. That combination of service commitments, payment terms and cooperation credit explains the enforcement significance: the announcement concerns negotiated resolutions and continuing investigations, not an adjudication of every disputed clinical or billing claim.

The Abbott settlement concerns allegations about powdered infant formula and nutritional products manufactured at its Sturgis, Michigan, and Casa Grande, Arizona, facilities. The agreement defines the covered period as January 1, 2018, through December 31, 2022. Government parties contend that Abbott failed to meet applicable manufacturing requirements and made inaccurate representations connected with purchases funded through WIC and Medicaid. Abbott denies the allegations. The agreement resolves specified civil claims arising from that covered conduct; it is not an admission that the disputed allegations are true.

The required settlement amount is $384,999,040.12 plus interest, divided among the federal government, participating state Medicaid programs and Massachusetts WIC. The federal release is conditioned on receipt of the federal payment, so an executed agreement alone does not establish completed payment or collection. Reserved claims include criminal liability, specified administrative remedies, other conduct and personal-injury or property-damage claims. The agreement also treats specified investigation, defense, corrective-action and settlement costs as unallowable government-program costs and requires separate accounting. These limits matter when evaluating what the resolution settles and how related costs may enter government contracts or Medicaid cost reporting; later payment performance was not independently established for this edition.

OIG’s September 17 Methodist Hospital audit examined 100 inpatient and outpatient claims totaling about $1.43 million for services in 2020 and 2021. Twenty-seven did not fully comply with Medicare billing requirements, producing $256,926 in net overpayments in the reviewed claims. OIG separately estimated at least $12.4 million in net overpayments for selected service types within a $62 million payment population. That larger figure is an estimate, not the amount found by adding the sampled errors. OIG recommended a refund, consideration of later-period internal audits and additional training. Methodist disagreed with the refund and internal-audit recommendations and said it was willing to provide education.

The September 16 McLeod Regional Medical Center audit reviewed 115 claims totaling about $1.52 million for the same 2020–2021 period. Seventeen did not fully comply, resulting in $38,676 in net overpayments. OIG again identified failures to follow billing policies within the selected risk areas and recommended a refund, consideration of later-period audits and training. McLeod agreed with most findings and said it would refund the agreed overpayments, without formally concurring or nonconcurring with the recommendations. Both hospitals were selected for potentially high-risk claims. Their results therefore support targeted control testing rather than treating the sample error rates as representative of every hospital claim, or the recommendations as court judgments or completed recoveries.

The September 23 DOJ announcement describes a $1 million settlement with RegalCare Management Group, RegalCare Management 2.0, owner Eliyahu Mirlis and executive Hector Caraballo. It resolves federal and Massachusetts allegations about medically unreasonable or unnecessary skilled-nursing rehabilitation services. The agreement includes admitted facts concerning Medicare services in 2018–2019 and MassHealth services in 2018–2023. It distinguishes the governments’ wider allegations from those admissions. Some Medicare claims at the former Ultra High RUG level were not supported by individual patient need and should have been billed at a lower level. These are historical payment classifications, not instructions to use that model today.

The primary agreement identifies Caraballo as a Licensed Practical Nurse and vice president of clinical reimbursement. It says MDS assessment changes were permitted regardless of professional licensure when they accurately reflected patient status, with Registered Nurse certification required. Caraballo made changes without visibly assessing or speaking with patients; some occurred without clinician consultation, while others followed consultation and/or record review. An RN signed off at his request. Mirlis also directed some claims to be billed before assessments were finalized. Those distinctions make patient-specific accuracy, certification and billing sequence the control issues. The separate Stern Therapy resolution was announced in March. The September agreement provides for $1 million plus interest and conditional relator payments; neither the announcement nor its October 6 update proves payment was completed.

DOJ’s September 30 announcement describes a $22.5 million False Claims Act settlement with Independence Blue Cross. The government alleged that IBX submitted inaccurate diagnosis data for Medicare Advantage enrollees, failed to withdraw that data and repay associated overpayments, and falsely certified its accuracy. Medicare Advantage organizations receive monthly payments adjusted for factors affecting expected healthcare costs. Diagnosis codes therefore influence the payment amount, making the correction or deletion of unsupported data financially significant as well as a coding-control issue.

For payment years 2017 through 2021, the government contends that nurse chart reviewers identified conditions supporting additional diagnosis submissions, while some previously submitted diagnoses were not substantiated. IBX allegedly used the reviews to seek more payment but did not delete unsupported diagnoses when the same work indicated overpayment. The settlement also resolves a former employee’s whistleblower lawsuit, with a $3.825 million share reported for that individual. DOJ states that the resolved claims are allegations and that liability was not determined. The case illustrates the risk of one-sided chart-review workflows; it is not a new CMS coding rule or proof that every disputed diagnosis was fraudulent.

DOJ’s September 30 announcement says Signal Diagnostics agreed to pay $20.5 million to resolve False Claims Act allegations concerning HRSA’s COVID-19 Uninsured Program. The program reimbursed eligible providers for services to uninsured people from approximately May 2020 through April 2022. Signal submitted testing and specimen-collection claims from October 2020 through March 2022. The government’s retention allegation covers a different period, January 2022 through May 2023, when Signal allegedly avoided obligations to repay amounts received for patients who had insurance.

According to DOJ, an internal audit begun around January 2022 identified ineligible claims. The alleged errors included duplicate profiles for the same patients with conflicting insurance information and claims submitted despite alternative coverage being on file. The government contends that Signal continued auditing and calculating the overpayment while knowingly and improperly avoiding repayment through May 2023. That sequence makes the connection between eligibility review, quantification and refund decisions central to the case, rather than treating the audit itself as the completed remedy. The settlement resolves allegations only, with no determination of liability; it does not reopen the closed reimbursement program or establish that settlement funds were already collected.

DOJ’s October 2 release reports a Western District of Michigan jury conviction of Jonathan Decker for conspiracy to distribute controlled substances and six distribution counts. The department describes his distribution of more than two million stimulant pills through the Done platform and more than $1 million in prescribing compensation. It says prescriptions were issued without patient examinations, including to people with substance-use disorders or significant psychiatric conditions. The release states that no sentencing date had been set. Its 140-year statutory maximum is potential exposure, not a prison term already imposed.

The account identifies concrete warning signs beyond prescribing volume: continued stimulant prescriptions after psychiatric concerns were communicated, pharmacy refusals, and referral bonuses for recruiting other prescribers. Those details connect clinical assessment, warning escalation and compensation incentives. DOJ identifies Decker as the eleventh convicted individual in the wider Done matter, while describing Done Global’s corporate charges as pending. The broader conspiracy’s reported 37 million pills should not be substituted for Decker’s individual two-million-pill figure. Readers should distinguish the proved individual verdict, the department’s description of the wider operation and allegations against a corporate defendant that had not yet been resolved in the cited release.

DOJ’s October 2 announcement reports Ahsan Ijaz’s guilty plea to conspiracy to commit healthcare fraud in a scheme involving approximately $65 million in New York Medicaid claims. Ijaz was an owner of Happy Family Social Adult Day Care Center, Family Social Adult Day Care Center and Responsible Care Staffing, a home-health fiscal intermediary. The release describes claims for adult day-care and home-health services that were not provided. The scheme amount is not identified as an individual fine or restitution order.

According to the court documents summarized by DOJ, the businesses paid cash kickbacks and bribes over roughly seven years to induce Medicaid recipients to enroll. Claims included services supposedly delivered while some recipients were outside the United States. Ijaz was the tenth defendant to plead guilty in the matter. The announcement scheduled sentencing for March 10, 2027, and stated a ten-year statutory maximum; neither establishes the sentence that a judge would later impose. The operational significance lies in connecting enrollment incentives, attendance or travel information and evidence of actual care before claims are billed, rather than relying on enrollment alone as proof of service.

The Justice Department announced on October 6 that AIDS Healthcare Foundation, or AHF, agreed to pay $1.44 million to resolve False Claims Act allegations involving Medicare Advantage diagnosis codes. Medicare Advantage payments reflect beneficiaries’ health risks, so diagnoses reported to CMS affect payment amounts and must have medical-record support. AHF’s Managed Care Division, doing business as Positive Healthcare Partners, operated special-needs plans for beneficiaries with HIV in Florida, Georgia and California. The government alleged failures to investigate and delete inaccurate or undocumented codes for payment years 2017 through 2023. It separately alleged unsupported HIV diagnoses, code B20, for payment year 2017 without documentation of a face-to-face visit.

According to DOJ, coders kept Delete Research spreadsheets identifying potentially unsupported diagnoses that needed investigation. The government alleged most of those codes were not deleted until 2024 or 2025, after AHF learned of the federal investigation. DOJ said AHF knew it had to investigate and delete inaccurate and unsupported codes within 60 days; that is an allegation in this historical case, not a new universally applicable deadline established by the announcement. DOJ credited cooperation, compliance enhancements and remedial deletions in the resolution. The settled claims remain allegations, and there was no determination of liability.

DOJ’s September 17 release describes a False Claims Act complaint against former Capstone Diagnostics executives Jay Johnson and Austin Whiles and associated entities. The complaint alleges that genetic testing at church health fairs and religious conferences was generated without valid treating-provider orders. It also alleges that medically unnecessary respiratory pathogen panels were added to COVID-19 testing for senior living communities. Across the two alleged schemes, Medicare paid approximately $13.7 million from 2019 through 2021. This amount is alleged program payment, not an awarded civil judgment.

The alleged mechanisms included copied physician signatures, broad standing orders, standardized diagnosis codes, sales staff entering orders and remuneration tied to testing volume. DOJ separately reported settlements with Capstone and its owner for $14.3 million and with billing company VitalAxis for $300,479. Those resolutions concern the settling parties and do not establish liability against the former executives in the pending complaint. Johnson’s related criminal charges were also pending in the announcement. For readers, the practical distinction is between an alleged ordering-and-marketing pattern that warrants control testing and a judicial determination that has not been reported.

DOJ’s September 17 announcement says Remedi SeniorCare Holding Corporation agreed to pay more than $5.3 million to resolve False Claims Act allegations involving prescription drugs dispensed to assisted-living residents in several states. The government alleged that Remedi billed Medicare and Medicaid from January 1, 2015, through March 31, 2021, despite lacking valid prescriptions. The settlement is based on the company’s ability to pay and is to be paid over time. Those terms do not establish that the full amount had already been received.

The resolution includes claims brought by former employees Maureen Gearhart and Laura Griffieth under the False Claims Act’s whistleblower provisions. DOJ says they will receive a share of settlement payments made over time. The matter involved DOJ’s Civil Division and the Southern District of Ohio, with assistance from HHS-OIG and the Ohio Attorney General. The resolved claims remain allegations, with no determination of liability. The operational concern is the connection between dispensing authorization and reimbursement: pharmacy and facility controls need to identify when the supporting prescription is absent or invalid before a federal-program claim proceeds.

DOJ’s September 21 announcement says Crown Medical Solutions and owners Michelle and Philanzo King agreed to pay $825,000 to resolve False Claims Act allegations. Crown supplied durable medical equipment, including knee braces, heel stabilizers and back braces. The government alleged that, from November 1, 2017, through April 30, 2019, the company and its owners billed Medicare for equipment that was not medically necessary, was not properly prescribed by a physician, or both. The settlement amount was based on the defendants’ ability to pay.

The resolution includes whistleblower claims brought by Karen Martinelli in a Northern District of Georgia case; DOJ reported that she would receive approximately $123,750 of the settlement. The release expressly states that the resolved claims are allegations and that liability was not determined. It therefore does not establish an admission of fraud or completed receipt of the settlement amount. For a comparable DME supplier, the case-specific lesson is to connect the equipment billed with a valid physician order and documented medical necessity. The release does not describe the executive assessment-editing conduct found in the separate RegalCare matter.

California’s September 21 announcement reports that Maki Martinez-Gruninger pleaded guilty to one felony count of Medi-Cal false claims and would serve two years in state prison. The investigation identified $413,643.30 in false In-Home Supportive Services and respite-care claims involving a disabled family member. This is a criminal resolution, not a civil settlement. The announcement reports the plea and prison outcome; it does not establish that restitution had been collected or that a separate new prosecution occurred in October.

The matter began with a complaint from the individual described as the disabled family member’s sole caregiver. According to that complaint, the caregiver discovered in December 2019 that Martinez-Gruninger had secretly applied to be the family member’s IHSS provider in November 2007. The reported investigation found that she intended to defraud the state and presented false claims over more than a decade. That history makes provider identity, beneficiary or caregiver complaints, and reconciliation of claimed care with actual service delivery central to the case. It does not support importing unrelated allegations about executives changing clinical therapy assessments.

The retained CDPH State Enforcement Actions Details export identifies 16 penalty records with issue dates from September 21 through 25, covering 15 facility identifiers. Eight records are classified as patient care, six as abuse not self-reported by the facility, one as willful material falsification and one as physical environment. Intercommunity Care Center has two separate penalty records, which explains why the number of citations exceeds the number of facilities. The selection includes skilled-nursing facilities and other licensed facility types, rather than only nursing homes.

The same export shows an Open disposition for all 16 records, while some rows have a zero balance. Open therefore should not be read as proof of unpaid penalties, a pending lawsuit or a particular appeal result. The dates when penalties were issued also differ from the earlier violation dates recorded in the rows. These are historical September citations; the retrieved export contains no penalty-issue-date matches for October 4–10. The data supplies categories, identifiers, assessed amounts and related metadata, but individual citation documents remain necessary before describing what happened to a patient or drawing case-specific conclusions.

Missouri’s Attorney General reports that Melissa Bates used her own phone to clock her daughter, Dajah Sanders, in and out as though personal-care services had been provided. Sanders was incarcerated from September 10 through 20, 2022, and could not have delivered the claimed care. The state describes eight purported service days, averaging about four hours each, and seven false claims causing $533.01 in Medicaid loss. Investigators’ analysis of deposits and withdrawals indicated that the Medicaid recipient and purported attendant were splitting the payments.

The Attorney General’s fuller account reports Bates’s healthcare-fraud guilty plea, suspended imposition of sentence and five years of unsupervised probation. It separately identifies $266.50 in restitution, $533.01 in double damages and a $2,500 civil penalty, totaling $3,299.51. Those are reported terms, not proof that the amounts were collected. The source also identifies Sanders’s earlier guilty plea and November 24, 2025 disposition. The case supplies a specific reason to compare clock-record submitter identity and worker availability with evidence of actual care: an electronic clock entry alone did not establish that the named worker could have performed the service.

The DOJ account identifies Hassan Ahmed Hussein and Ahmed Abdirashid Mohamed as operators who enrolled Pristine Health LLC as a Medicaid provider for Minnesota’s Housing Stabilization Services program. The business promised housing help for people with disabilities but submitted claims for services never provided and inflated claims for higher reimbursement. It enrolled approximately 90 beneficiaries, including some who had not agreed to receive services, and billed Medicaid more than $820,000. That billed amount is distinct from the more-than-$500,000 fraud amount in the shorter OIG summary.

Hussein pleaded guilty on September 24, 2026, and Mohamed on October 1; both pleaded to one wire-fraud count. The cited release says sentencing dates would be set later and reports a twenty-year statutory maximum, rather than an imposed prison term. The account describes the HSS program as defunct, so this case should not be read as instructions for a currently open enrollment pathway. Its operational relevance is the gap between provider enrollment and delivered services: beneficiary agreement, individual service records and actual housing-support work need to support claims, rather than treating an enrollment record as proof that care occurred.

DOJ’s September 30 release reports a September 17 indictment of Nouman Mustafa and Mohsin Khan on healthcare-fraud and aggravated-identity-theft counts. Mustafa had been arrested at Los Angeles International Airport on February 11 while attempting to board a one-way flight to Pakistan; Khan was arrested September 29 in Bakersfield. According to the government’s account of court records, the defendants created DME companies between January 2025 and January 2026 that appeared legitimate but lacked locations where legitimate business could be conducted.

The government alleges that the companies quickly submitted more than $3.5 million in Medicare claims, using real beneficiary and physician information obtained through contacts abroad. A company was typically used for weeks or months until fraud-related denials began, followed by a shift to another entity. DOJ says the defendants retained approximately 30 percent of proceeds and sent the rest to their contacts. These are allegations describing a supplier-identity and claims pattern, not findings that every virtual supplier is improper. The defendants are presumed innocent; the release’s potential statutory penalties are not imposed sentences.

The September 29 DOJ announcement describes a False Claims Act lawsuit against Dr. Michael Neret, who owns and manages Neret MD Medical Clinic in Bay City and Lake Jackson. The complaint alleges nearly $500,000 in Medicare billing for surgical neurostimulator electrode implantations. DOJ describes those billed procedures as complex surgeries requiring an operating room and reimbursed at thousands of dollars each. The central allegation is that the surgeries billed were not the services patients actually received.

Instead, the complaint alleges that non-physician practitioners and non-clinical staff used inexpensive electro-acupuncture devices during short office visits, inserting small wires into patients’ skin and securing devices behind their ears. It further alleges that Neret encouraged use of devices he knew were not billable and used the procedures to justify pain-management narcotic prescriptions. DOJ expressly states that the claims are allegations and that liability has not been determined. The case therefore supports comparison of codes, setting, equipment and clinical documentation; it does not establish a judgment, settlement or blanket prohibition on legitimate neurostimulation treatment.

Georgia’s Attorney General announced September 29 that a Chatham County grand jury had indicted Latisha Blake-Ulmer on three counts of neglect of a disabled adult. The indictment resulted from evidence presented September 23. The state says Blake-Ulmer managed and cared for disabled adults in a Savannah group home. Its Medicaid Fraud and Patient Protection Division investigated after a complaint from the Georgia Department of Behavioral Health and Developmental Disabilities.

The allegations concern repeated occasions when residents were locked outside without adequate clothing or weather protection. The state also describes a resident whose severe bruising and fractured collarbone allegedly went unaddressed for several days while under the defendant’s custody and control. These details identify supervision, protection and response to injury as the case-specific concerns. The Attorney General’s notice expressly preserves the presumption of innocence and the prosecution’s burden to prove the charges. It does not report a conviction, sentence or an adjudicated conclusion about the practices of other residential providers.

New York’s September 28 announcement reports the arrest of Suleman Nasimi and separate forty-count felony complaints against him and Tooth Fresh Meadows. Prosecutors allege more than $300,000 in Medicaid billing for hundreds of unperformed dental procedures between January 1, 2020, and August 31, 2024. The alleged procedures included root canals and porcelain crowns affecting at least 35 Medicaid recipients. The charges include grand larceny, healthcare fraud and offering false instruments for filing.

The Attorney General alleges that more than $140,000 was billed in July 2022 alone during periods when the office was closed and Nasimi was traveling in Europe. The alleged harm extends beyond reimbursement: some patients were denied prior approval for needed care elsewhere because Medicaid records already showed the procedures as performed. Those assertions connect claim accuracy with future access to treatment, not merely an accounting discrepancy. The defendants are presumed innocent. The announcement’s possible prison range is contingent on conviction and should not be presented as a sentence already imposed.

The FTC’s announcement describes a joint lawsuit with Utah and Nevada against Lens.com, owner Cary Samourkachian and affiliated Speed Commerce LLC. The complaint alleges that low prices in search ads and on the website became much higher prices at checkout through mandatory charges labelled Taxes & fees. According to the agencies, those charges routinely doubled advertised prices, were positioned outside the visible portion of checkout and could be bypassed by following a prominent Continue prompt without seeing the fee line.

The allegations also concern the nature of the label and recurring purchases. The FTC says the label suggested sales taxes even where contact lenses were tax-exempt, and that AutoRefill enrollment did not clearly disclose the same mandatory fees before billing information was obtained. The complaint further challenges disclosure of cancellation instructions and the deadline to avoid the next shipment. It alleges federal and state consumer-protection violations and was filed in federal court in Nevada. These are complaint allegations, not a judgment or settlement; the FTC states that the court will decide the case.

The eight-page MediExcel Health Plan agreement jointly addresses enforcement matters 20-450 and 24-456. Both cited DMHC URLs display the same combined agreement, which specifies one $50,000 administrative penalty and a corrective-action plan. The letter is dated July 29, was accepted by the plan September 4 and executed by DMHC September 27. Follow-up reviews of the 2018 and 2021 surveys identified five unresolved deficiencies across grievances and appeals, quality assurance, utilization management and emergency services.

The agreement describes missing policy detail for assistance to people with visual or communication impairments, insufficient evidence that monitoring was implemented, defective required grievance-notice wording and use of an incorrect emergency-payment standard in two of three relevant reviewed files. It required a certified correction statement, a compliant grievance-acknowledgment template and an emergency-services payment policy, all due September 30. Those specific documents connect correction claims with evidence the regulator can examine. The execution date is distinct from website publication, and the agreement alone does not establish later payment or completion of those deliverables.

Adventist Health Plan’s nine-page DMHC agreement concerns unresolved deficiencies from a routine survey and follow-up process. The plan is restricted: it does not directly enroll members, but supports other licensed plans’ Medi-Cal enrollees in specified areas. The agreement describes generic delegate policies that left its own quality and utilization-management responsibilities unclear. A follow-up report found that the five original deficiencies had not been cured. The letter is dated September 3, was accepted September 18 and executed by DMHC September 27, with a $40,000 administrative penalty.

The file review found deficient explanations, criteria or clinical reasoning in 44 of 61 denial or modification files, including 34 that entirely lacked letters to enrollees. Nine of the 61 reviewed decisions were untimely: six involved concurrent review and three preservice review. These figures identify specific oversight and communication weaknesses, rather than a conclusion that every delegated decision was defective. The plan acknowledged noncompliance for this enforcement matter, while the agreement limits use as an admission in other civil or criminal proceedings. Later penalty payment and remediation completion were not established by the agreement.

DMHC’s agreement with Central California Alliance for Health concerns the quarterly grievance report for the period ending December 31, 2025. The report was due January 30, 2026, but filed March 26, fifty-five days late. DMHC emailed about the missing report March 5 and received no response until the filing date. The letter explains that this quarterly report covers grievances pending and unresolved for thirty days or more, and must be filed within thirty days after the quarter. The agency imposed a $2,750 administrative penalty and accepted a corrective-action plan.

The agreement records both corrective deliverables as completed August 19: addressing the cause of the late filing and delayed response, and documenting steps to ensure future filings are timely. They should therefore be treated as reported completed work, rather than new future deadlines for the plan. The letter and plan acceptance are dated September 11, with DMHC execution September 27. Those dates do not establish when the document was posted online. The agreement does not independently establish later penalty payment or closure of matters beyond the specified reporting deficiency.

CDPH’s State Enforcement Actions export records citation 020023853 for Bay View Rehabilitation Hospital, LLC, an Alameda County skilled nursing facility. The citation was issued September 28, 2026, and is classified as Class A under the Patient Rights category, citing Title 22 section 72315(b). The export lists $3,500 as the assessed amount and balance and identifies the East Bay District Office. These are the details of a specific citation record, rather than a new statewide patient-rights requirement.

The violation date in that record is May 24, 2026, several months before the citation’s issue date. Its disposition is Open in the retained October 11 export. Neither the open status nor the balance field establishes a final appeal outcome, and the category and citation code do not explain what happened to a resident. The full citation document would be needed to evaluate the incident and any facility response. For a provider comparing its own controls, the appropriate next step is to obtain that document and distinguish its factual findings from the export’s administrative metadata.

OIG’s audit of UnitedHealthcare Benefits of Texas, Inc., contract H0609, examined selected diagnosis codes at high risk of miscoding in Medicare Advantage risk adjustment. Issued September 23 and posted September 28, report A-07-24-01215 found that records did not support selected diagnoses for 172 of 230 sampled enrollee-years. The sample produced $622,927 in identified overpayments; OIG extrapolated at least $24.4 million for 2020 and 2021. An enrollee-year is the sampling unit here, not a count of unique patients.

MA payments depend in part on diagnoses submitted to CMS, so unsupported codes can affect payment even when the underlying encounter occurred. OIG said United’s prevention, detection and correction controls could improve and made four recommendations, including a refund of the estimated amount. United disagreed with some findings and requested withdrawal of all recommendations. The selected high-risk sample does not establish that all diagnoses submitted by the plan were unsupported. The findings warrant review of documentation and correction controls while preserving the difference between an audit recommendation and an adjudicated debt or completed recovery.

OIG’s report A-09-24-03009, issued September 23 and posted September 28, examined kidney-transportation reporting and organ transport at 43 selected independent organ procurement organizations. It found $188,147 in improperly allocated or insufficiently supported costs reported by 21 OPOs and another $240,178 reported by 26 OPOs, totaling $428,325 in unallowable costs. Those groups fall within the 43 reviewed organizations and should not be added together as 47 separate OPOs. Four OPOs also failed requirements for organ preparation and transport.

OPOs coordinate procurement, preservation and transportation, and the audit followed concerns about wide variation in reported transportation costs and ineffective practices resulting in lost or damaged organs. OIG recommended that CMS instruct the Medicare administrative contractor to recover the questioned costs through cost-report adjustments and provide additional education. CMS concurred with both recommendations. The report identifies financial-reporting and handling concerns, but does not establish organ harm at every reviewed OPO or confirm completed collections. Cost allocation, supporting records and actual transport practices are distinct parts of the resulting control review.

OIG’s South Carolina audit, OAS-25-04-114, was issued September 30 and posted October 2. It found that the state did not accurately calculate and report approximately $108.6 million in the federal share of Medicaid and CHIP collections subject to increased COVID-19 matching rates. Collections include recovered overpayments, refunds and similar receipts that reduce net program expenditures and the federal funding due. The temporary increases were 6.2 percentage points for Medicaid and 4.34 percentage points for CHIP, making the applicable rate material to the federal share.

OIG made four recommendations, including adjustment of future CMS reports and refund of approximately $108.6 million in underreported collections, with $8.6 million relating to the first quarter of the increased rate. It also recommended reporting amounts supported by accounting records and written procedures for unexpected or retroactive matching-rate changes. South Carolina concurred with three recommendations and described actions taken and planned. The finding concerns state financial reporting; it is not a fine imposed on providers or proof that every recommended refund has been paid. The earlier $61.8 million audit discussed as background is a separate figure.

OIG’s Wisconsin school-based services audit, A-02-24-01020, examined $505.5 million in reimbursement during a four-year period. Issued September 30 and posted October 2, it estimated at least $67 million in improper federal reimbursement associated with unsupported random moment time-study coding and services by unlicensed providers. OIG questioned an additional $387.9 million because the state could not support allocation ratios. Time studies estimate the portion of personnel activity attributable to particular services, making both coding and allocation support important to reimbursement.

The six recommendations include refunding the $67 million estimate and either refunding $387.9 million or providing documentation reasonably supporting the ratios. OIG also identified potentially unallowable costs because studies did not sample moments at the beginning of the school year. Wisconsin generally disagreed, agreed in part with the first finding, disagreed with the second and did not clearly state a position on the third. The conditional refund-or-substantiate recommendation must remain distinct from an unconditional established liability. Organizations comparing their own programs should examine time-study evidence, provider qualifications and allocation documentation together.

North Carolina’s October 1 announcement states that White Oak Manor of Burlington will pay $98,474 to resolve allegations involving an unqualified nurse, including $49,237 in Medicaid restitution. The Attorney General says Nieasha Jones was hired without a nursing license, training or experience and worked 54 shifts over three months, interacting with residents and providing care. The facility allegedly billed Medicaid for services to those residents, including services Jones provided. The announced amount is a settlement commitment, not confirmation that payment has been received.

The state’s Medicaid Investigations Division investigated after a referral from the Department of Health and Human Services’ Division of Health Service Regulation. The release expressly says the civil claims remain allegations and that there was no judicial determination or admission of liability. Its concern is the named hire and period of care, not a finding that every employee or service at the facility was unqualified. The case connects verification at hiring with continued staffing records and the services included in claims; a license check detached from actual assignments would not address that connection.

DOJ reported sentencing of four participants who had pleaded guilty to conspiring to distribute schedule II controlled substances and acquire promethazine-codeine solution by fraud. Yared Michael Tesfaye received sixty months; Elhadj Malick Diallo received time served, approximately thirteen months; Cameron Isaiah Lewis received eight months; and Raymono Alfonzo Russell II received ten months. These are the four defendants identified in the release, separate from the physician involved in the wider conspiracy. The different terms should not be combined into a single sentence or confused with statutory maximum exposure.

According to court documents described by DOJ, the 2023–2024 scheme used lists of purported patients, variations of names and false addresses to send prescriptions to pharmacies in multiple states. Tesfaye sold appointment slots with the physician, while Lewis and Diallo paid $300 per fraudulent prescription, collected drugs and distributed them for profit. The investigation began after Russell attempted a pharmacy pickup in September 2023 and officers found prescription bottles in multiple patient names from the same prescriber. Those details connect prescriber, patient-identity and pickup patterns across locations, supporting coordinated review of unresolved red flags rather than examination of each prescription in isolation.

DOJ’s October 2 release reports Tekiyah McLeod’s guilty plea to healthcare fraud and aggravated identity theft. She served as registered agent for nLove Community Services LLC, which purported to provide mental-health therapy to Medicaid beneficiaries. McLeod admitted billing approximately $477,872 for therapy never provided, including purported services to herself. She used a nurse practitioner’s name and National Provider Identifier without the practitioner’s knowledge or consent, and received approximately $453,323 from Medicaid. Claimed amounts and payments received are separate measures here.

The court accepted the plea and scheduled sentencing for December 16; McLeod remained on bond in the dated release. DOJ described potential healthcare-fraud imprisonment and a mandatory consecutive identity-theft term, but did not report an imposed sentence. The unauthorized use of the practitioner’s identity is also not evidence that the practitioner participated. For providers reviewing their own billing, the admitted conduct connects encounter evidence, rendering-provider authorization and claim submission. A valid NPI appearing on a claim does not by itself demonstrate that its holder provided or authorized the reported service.

DOJ’s October 2 announcement reports that Jerry Jones III, a former emergency physician in Mequon, Wisconsin, was sentenced October 1 to 27 months in prison. He had pleaded guilty June 29 to conspiracy to distribute controlled substances outside usual professional practice and without a legitimate medical purpose. The described conduct occurred from 2021 through 2025 at a residence-based clinic purporting to offer addiction treatment by telehealth. The sentence date and the following day’s release date are distinct.

According to the release’s account of court records, Jones prescribed buprenorphine, benzodiazepines and stimulants for cash without demonstrated medical necessity, charging more for higher doses and more prescriptions. He received $294,850.72 through CashApp and Venmo; that figure describes proceeds, not a separately announced fine. The sentencing judge considered his long prior lawful practice and voluntary license surrender but imposed imprisonment for seriousness and deterrence. The lesson is tied to the admitted absence of legitimate care and the prescribing incentives in this case, rather than a prohibition on clinically appropriate medication or telehealth treatment.

DOJ’s September 29 announcement reports federal charges against Swapnadip Roy and Vicky Ramancha in a transnational counterfeit-prescription-drug scheme. The indictment alleges that they obtained counterfeit Ozempic from unauthorized sources in China and sold it at deep discounts to distributors in the United States. Roy was extradited from Italy and made an initial appearance in Tampa. The case alleges conduct from at least July 2023 through April 2024, rather than announcing a completed criminal adjudication.

According to the allegations, counterfeit packaging, inserts, pen labels and needles were intended to make downstream purchasers believe they had authentic manufacturer-authorized Ozempic. The scheme allegedly continued after an FDA seizure and public warning in December 2023. The defendants face conspiracy, smuggling and counterfeit-drug counts; the release’s potential maximum imprisonment is contingent on conviction and is not an imposed sentence. The allegations support verifying authorized distribution channels and preserving suspect product and packaging evidence, while avoiding an assumption that appearance or a low-price offer alone establishes authenticity.

DOJ reported a 200-month prison sentence for Joseph Toews, a Manhattan Beach family therapist, following his June 23 guilty plea to production of child sexual abuse material. The court also imposed a $50,000 fine, a separate $55,000 special assessment and twenty-five years of supervised release after imprisonment. Those financial orders and the later supervision term are distinct from the prison sentence and do not establish that any ordered amount has been collected.

The release describes a camera installed in January 2023 in a stall of a publicly available women’s bathroom in the same building as his office. At least eleven videos recorded minor victims, some of whom received therapy from him. The location was a shared building bathroom, not necessarily a private treatment room. Without identifying victims or repeating graphic details, the case supports safeguarding reviews that include shared patient-accessible facilities, unauthorized devices and installation access. The criminal disposition should not be characterized as an OCR HIPAA settlement or used to imply that every recorded person was a therapy patient.

James Vincent Campbell, founder and CEO of Axim Fringe Solutions Group LLC, pleaded guilty September 29 in Maryland to theft from an ERISA benefit plan. Axim processed employee benefits for federal contractors, receiving money intended for health-insurance premiums and retirement contributions and forwarding it to carriers and retirement accounts. DOJ describes more than $8.8 million unlawfully converted from clients through withdrawals from a pooled master trust and repeated excess charges. The case therefore concerns money entrusted to an intermediary, rather than claims for medical services.

The account of court documents identifies 135 unauthorized withdrawals totaling $2,486,905 during 2015–2024, followed by secretly charging some clients up to five times their agreed fees after the business moved to Arizona. The withdrawal figure is part of the overall loss, not a separate additional $8.8 million. Sentencing remained for the judge to determine, with a statutory maximum of five years. For employers and plan fiduciaries, the control issue is whether contributions actually reach their intended recipients and whether deducted fees match the agreement; an intermediary’s statement alone does not reconcile the carrier or trust receipt.

DOJ’s October 7 release reports that Heal 360 Urgent Care PLLC, Heal 360 Primary Care PLLC and owner Mohammed Amer Mohiuddin agreed to pay $20 million to resolve False Claims Act allegations. The government alleged unperformed evaluation-and-management services were billed to the HRSA Uninsured Program from January 1, 2021 through March 23, 2022. It distinguishes specimen-collection code 99211 from higher-level office-visit codes, rather than treating a test itself as evidence of an evaluation.

According to the government, walk-up and drive-through patients received specimen collection without other treatment, while template records created the appearance of higher-level visits. Remote scribes prepared records and Mohiuddin appeared as rendering physician on most claims despite not treating those patients. The settlement resolves two whistleblower cases, with a related asset-forfeiture agreement crediting property-sale proceeds toward the civil settlement. These remain allegations without a determination of liability. The control question is whether billed services occurred and the record reflects them.

DOJ’s October 8 release reports that a federal jury convicted Sharmaine Meadows the previous day of three healthcare-fraud counts involving Minnesota’s now-defunct Housing Stabilization Services program. Evidence showed that the program paid her company more than $3.6 million during 2020–2025 for services that were not provided. The program allowed up to 150 hours each for transitional and sustaining services per eligible beneficiary, and Meadows pressed employees to maximize billing to those caps even when the hours were not delivered.

The evidence described purported in-person services by employees in other states or countries, claims while beneficiaries were hospitalized, and employee totals exceeding twenty hours a day for weeks. Beneficiaries testified that they received little or no assistance but were told their available hours were exhausted. The problem was not merely incomplete notes: the time, location and service circumstances contradicted delivery. The verdict establishes convictions, but the release schedules sentencing later and cites only maximum possible penalties. Organizations reviewing similar services should test actual delivery and conflicting time or location evidence rather than treat a program allowance as proof of work performed.

DOJ’s October 9 release reports that Mark Loftis was sentenced the previous day to fourteen years in prison after a July jury conviction for healthcare-fraud and wire-fraud conspiracy. The case involved Back Pain Home Supplies LLC, doing business as EZ Medical Supply, and more than $30 million in false claims for braces, continuous glucose monitors and other DME. Medicare, TRICARE and CHAMPVA paid more than $8 million. Loftis and others hid ownership and management information and concealed unenrolled entities billing through the supplier.

The court-record account describes more than $1 million in kickbacks, including payments through a shell marketing company, and purchases of sham telemedicine orders from clinicians who had not examined and often had not spoken with beneficiaries. One example involved eight braces billed for a single beneficiary. The court also ordered more than $8 million in restitution and more than $560,000 in forfeiture; those are orders rather than proof of collection. The case connects enrollment transparency, marketing compensation, independent clinical orders and actual beneficiary need. It does not make legitimate telemedicine or clinically supported DME inherently improper.

DOJ’s October 7 announcement reports the previous day’s conviction of Joseph Rodriguez, a laboratory vice president and owner of marketing company Phoenix Health. At drive-through events at residence country clubs, patients seeking COVID swab and antibody tests received many additional blood tests they did not want or need and that no doctor had ordered. Trial evidence described claims for those tests as medically necessary and attributed them to a treating physician. The jury convicted Rodriguez of conspiracy and six substantive healthcare-fraud counts.

The events involved nine clubs, about four months and almost two thousand patients, with more than $15 million billed to Medicare and more than $500,000 paid. Trial evidence included complaints from patients, a doctor whose name appeared as ordering clinician and club managers questioning the extra testing. These details connect marketing arrangements with actual orders, patient needs and complaint escalation. The release states that sentencing would be scheduled for January 2027 and gives only maximum possible penalties, not an imposed sentence. The conviction concerns the proven scheme; it is not a general prohibition on clinically ordered additional testing.

New York’s October 7 release reports the arrest and indictment of Miguel Baron, Guardiola Pharmacy and Baron Specialty Pharmacy. The Attorney General alleges that, from January 2023 through April 29, 2026, recipients were offered cash incentives, often $150–$250, to fill prescriptions and sometimes sell medication back. Repurchased HIV medications allegedly returned to inventory for dispensing and repeated reimbursement, while other drugs came from unlicensed sources. The state alleges more than $31 million in Medicaid and AIDS Drug Assistance Program reimbursements.

The allegations raise two connected concerns: patients may miss prescribed treatment after selling medication back, and other patients may receive products without assurance of proper storage or lawful sourcing. The criminal case includes healthcare-fraud, larceny, kickback and money-laundering charges. A separate civil forfeiture action seeks more than $95 million and concerns assets allegedly bought with proceeds; that request is not an additional amount already recovered. The defendants are presumed innocent. Pharmacy oversight should distinguish the pending allegations while examining inventory provenance, patient incentives and repeat-billing patterns together.

Jacqueline Pelphrey pleaded guilty October 6 in Hartford federal court to healthcare fraud. She owned and operated Women’s Health Resources Inc., doing business as Essentials for the Special Woman in Vernon, Connecticut, which sold post-mastectomy products including custom breast prostheses. According to the court-document account, beginning no later than August 2018 she submitted claims for custom products clients did not order, purchase or receive. The affected payers included Medicaid and other health insurance plans.

As part of the plea, Pelphrey admitted total losses of $1,299,633.10. She remained on bond pending a December 29 sentencing hearing in Bridgeport; the release describes a maximum possible ten-year term rather than a sentence already imposed. The admitted conduct makes the evidentiary chain from a patient’s actual order to custom production, fulfillment, delivery and claim material to the review. A product category or a supplier’s billing record alone would not establish that the particular patient requested and received the item. The case does not suggest that all custom prosthesis claims are improper.

DOJ’s October 6 announcement reports that Dr. Joseph A. Montes was taken into custody and appeared in federal court after unsealing of a twelve-count indictment returned September 30. The indictment alleges false claims to HRSA for office visits not performed during 2020–2022. Montes owned Joseph A. Montes MD & Associates, P.A. and Montes Medical PLLC and allegedly allowed others to operate pop-up COVID testing sites under his name, where patients received nasal swabs while office visits were billed.

The alleged volumes included more than three thousand evaluation-and-management claims on approximately twenty-nine dates and more than nine thousand on December 1, 2021, described as about one visit every nine seconds around the clock. The government alleges approximately $30 million in billing and $20 million paid, distinct figures rather than an imposed penalty. The indictment is an accusation, and Montes is presumed innocent. The specific control question is whether clinician presence, encounter duration and documented E/M work can support the claimed volume; a testing site’s operation under a physician’s name does not alone demonstrate those visits occurred.

An October 9 federal indictment charges Marc Aaron Potash, founder and CEO of Tiero LLC, with healthcare-fraud conspiracy, seven substantive fraud counts and five transactions involving criminally derived proceeds. DOJ alleges that the January 2022–May 2026 scheme submitted false claims to Medicare, Medicaid, the Federal Employees Health Benefits Program and other insurers. The alleged conduct includes false documents submitted to Maryland authorities to obtain CLIA certification and representations that clinicians performed testing at the company’s laboratory.

According to the indictment, Tiero instead shipped over-the-counter, self-administered COVID tests while claims listed false dates, places of service and rendering providers. DOJ alleges more than $100 million in false claims and more than $50 million in payments, neither of which is a fine or completed recovery. The defendant is presumed innocent, and the release’s possible prison terms depend on conviction. The case-specific issue is the mismatch between shipped products and the laboratory services represented to regulators and payers. Verification should connect certification representations with the actual test, location and provider reported on each claim.

DOJ reported three sentences on October 7–8 in an Amtrak health-plan fraud investigation involving payments to employees for their insurance information and claims for unprovided or unnecessary services. Physical therapist Jaekwan Lee received fifteen months on October 8 and $841,666 in restitution after allowing his license and business bank accounts to be used for fraudulent billing. Podiatrist Michael DeNicola received thirty-two months on October 7, with more than $1.6 million restitution and $1.3 million forfeiture, for healthcare-fraud conspiracy, unlawful controlled-substance distribution and unlawful firearm possession.

DeNicola’s conduct included sixty-four oxycodone prescriptions issued without legitimate medical purpose as part of the arrangement. Former Amtrak employee Devon Burt separately received twenty months and $959,072 restitution after recruiting employees and conspiring to threaten a participating provider for money. The wider investigation involved more than $11 million paid and nineteen guilty pleas; that total must not be attributed separately to each defendant or added again to their individual amounts. The cases connect patient incentives, use of provider credentials and accounts, and actual encounter evidence, with coercion requiring its own escalation to counsel and security.

DOJ reported that physician Le Thu was sentenced October 6 to thirty-six months in prison, two years of supervised release and more than $27 million restitution after 2025 guilty pleas. One scheme from May 2014 through April 2017 involved approximately $35 in kickbacks for each approved DME or compounded-medication prescription, with knowledge that some prescriptions would be billed to TRICARE. The release says TRICARE paid pharmacies hundreds of thousands of dollars for compounded medications obtained through those kickbacks.

A second scheme, from March 2017 through November 2020, involved genetic tests and DME orders for Medicare beneficiaries. Thu signed, and caused medically untrained people to sign, false documentation suggesting clinical judgment and patient care that had not occurred. She received more than $200,000, while the resulting Medicare claims exceeded $40 million and payments exceeded $27 million. Those figures describe different parts of the scheme, not interchangeable penalties. The case supports tracing an order to actual clinician involvement, accurate representations and compensation terms; it does not characterize legitimate telemedicine as inherently fraudulent or establish that restitution was collected.

DOJ’s October 6 announcement resolves allegations that Central Florida Pain Management failed to provide communication assistance under ADA Title III. A legally blind patient alleged that staff refused help completing required medical-history forms on a tablet in November 2024. Without assistance he could not finish the forms, was denied the scheduled new-patient appointment and had to reschedule. The alleged barrier concerned access to care, rather than a preference for paper over electronic records.

The agreement requires a written effective-communication policy, training for all employees, a log of requests for auxiliary aids and the practice’s responses, reporting of ADA complaints to the United States, and $2,000 in compensatory damages. The announcement does not supply separate completion dates or prove payment. Its practical lesson is to connect accessible technology with staff assistance and escalation when a patient cannot complete intake; adopting a digital form alone does not resolve the access problem.

DOJ’s announcement describes a judge-approved settlement resolving claims brought for Army National Guard combat medic Maria Opara against University Village Memory Care in Texas. Opara alleged that the employer demoted or attempted to demote her from night-shift supervisor to a lower-paid position because she took leave to fulfill military orders, then terminated her after she refused the demotion. The settlement addresses those employment claims under the Uniformed Services Employment and Reemployment Rights Act, rather than a patient-care or reimbursement allegation.

The agreement provides $15,000 in monetary relief and requires updated policies and procedures concerning employees’ USERRA rights, with training for all employees on those changes. The release explains that USERRA protects reemployment following military-service absences and prohibits discrimination because of military obligations. Its announced resolution is not evidence that every settlement payment or training requirement has already been completed. Healthcare employers reviewing their own processes should connect military leave, proposed reassignment and termination decisions, ensuring that supervisors escalate these decisions through HR and counsel before treating leave as a reason to reduce an employee’s position.

Three decisions published October 7 take effect November 6. MedPharm Research’s manufacturing application was denied after findings concerning commonly controlled affiliates’ unregistered manufacturing and recreational-market diversion; the order preserves a possible separate state-medical-license application route where applicable. Wellwise’s revocation follows unresolved dispensing red flags on at least 1,360 prescriptions. Arenbii’s revocation also concerns unresolved red flags, but DEA did not sustain a separate partial-fill allegation for insufficient facts. Both pharmacy registrations had already been immediately suspended in September 2025. These are administrative orders, and MedPharm’s application denial must not be described as revocation of an existing registration.

Three decisions published October 9 take effect November 9. Maui Clinic Pharmacy dispensed about three hundred controlled-substance prescriptions from an unregistered relocated site; an accountability audit found 4,779 unexplained dosage units across overages and shortages. Alexandra Lovec’s order rests on at least 109 prescriptions without legitimate medical purpose, inadequate examinations and records, and dangerous combinations. Vladimir Romaniv’s order addresses overlapping prescriptions, orders during a patient’s incarceration without examination, false clinic records and missing supervisor details; DEA did not sustain the stated thirty-day-limit theory for the schedule V codeine preparation. His New York registrations had been suspended in November 2025 and New Jersey controlled-substance authority expired in November 2023. Organizations should use each actual order and current status, not the later effective dates, to assess authority; a general prescribing lesson would miss the distinct manufacturing, location, inventory and rejected-allegation limits.

DOJ’s October 8 release reports a forty-year prison sentence and five years of supervised release for Matthew Hightower for using a firearm during a violent crime. The underlying May 2016 plot targeted a federal witness who had supplied information about healthcare fraud and a separate murder. The intended witness’s neighbor, Latrina Ashburne, was killed through mistaken identity. The release thus concerns violent retaliation linked to an investigation, rather than a new reimbursement or privacy-rule violation.

According to the account of court documents, Hightower used jail calls and letters to coordinate the plot while detained before trial. The court directed the new sentence to run concurrently, beginning that day, with the sentence he was already serving for a separate murder; it is not an additional forty years to be mechanically added. The healthcare-compliance connection is the need to route credible threats and retaliation concerns to security, counsel and appropriate authorities. Confidential reporting safeguards should be assessed without implying that ordinary reporting issues are equivalent to the extreme facts of this case.

DEA’s decision concerning St. Michael’s Pharmacy in Rosenberg, Texas, revokes registration FS0483951 and denies pending renewal, modification and additional Texas registration applications. Signed September 25 and published October 2, the final order is effective November 2, 2026. The agency describes unresolved prescription red flags, failures to maintain complete controlled-substance records and inventory, and failures involving original signed electronic DEA 222 order forms. The pharmacy defaulted in the administrative proceeding, making the factual allegations deemed admitted under that process.

The decision also finds that Texas pharmacy license 33705 was revoked, independently removing state authority required for DEA registration. The federal registration had already been immediately suspended by a September 10, 2025 order. The future effective date of the final revocation therefore does not authorize dispensing until November 2. For credentialing and pharmacy oversight, the case illustrates why a final order’s date cannot substitute for checking earlier suspensions and current state and federal authority. It is an administrative decision, not a criminal conviction.

DEA’s final decision revokes registration RB0369733 issued to By Grace Inc. Counseling Services, a Baltimore narcotic treatment program, and denies pending renewal, modification and additional Maryland registration applications. The order was signed September 25, published October 2 and is effective November 2, 2026. The agency describes recurring inventory errors over several years, controlled-substance overages and shortages, improperly combined records, and errors in DEA 222 forms and powers of attorney. Its findings go beyond an isolated clerical mistake.

DEA also found materially false registration applications involving an undisclosed controlled-substance conviction of the owner. That was an additional ground for the decision, alongside recordkeeping deficiencies. By contrast, the agency did not sustain the government’s allegation that the program ordered controlled substances without state authority, citing inadequate notice and insufficient evidence. That distinction matters when identifying the actual failures established by the order. Programs reviewing their own controls should connect dispensing and inventory records, authorized ordering and accurate officer-history disclosures, and retain evidence that corrective measures address the specific deficiencies.

DEA’s final order concerning Angela Turner-Brown, N.P., revokes registration MB0434035 and denies pending applications to renew or modify it, as well as other pending applications for additional Indiana registration. Signed September 15 and published September 29, the order is effective October 29, 2026. The agency found that her Indiana Controlled Substances Registration prescriptive authority expired October 31, 2023, and her Advanced Practice Registered Nurse prescriptive authority expired October 31, 2025. State records reviewed in the decision continued to show both as expired.

The decision also states that the DEA registration itself expired July 31, 2026. DEA retained jurisdiction to finish the administrative case despite that expiration, and the factual allegations were deemed admitted after default. This is an administrative determination, not a criminal guilty plea. The later October 29 effective date must not be read as permission to prescribe in the interim. Credentialing controls need to reconcile separate state prescribing authorities and federal registration, including expirations that predate publication of a final agency order.

DEA’s final decision revokes registration FN4962761 issued to Christopher Nadorff, M.D., and denies pending renewal, modification and additional Ohio registration applications. The order was signed September 21, published September 29 and is effective October 29, 2026. Its factual basis is loss of state authority: the State Medical Board of Ohio suspended the physician’s medical license effective October 8, 2025, and the state records noticed by DEA continued to show suspension when the order was signed.

The physician defaulted in the administrative proceeding, and DEA treated the factual allegations as admitted. The decision establishes the license suspension and its consequences for federal registration; it does not supply findings about the underlying conduct that caused the state suspension. Because the state restriction already existed, the later federal effective date is not an interim permission to practice or handle controlled substances. Credentialing teams should distinguish a professional-license restriction, the DEA registration decision and any independently verified later change in status, rather than infer reinstatement from the passage of time.

DEA’s final order revokes registration FF1775660 issued to Jorge J. Figueroa, M.D., and denies pending renewal, modification and additional New Jersey registration applications. Signed September 21 and published September 29, the order is effective October 29, 2026. The agency found that a December 6, 2017 guilty plea in federal court in New Jersey led to mandatory exclusion from Medicare, Medicaid and all federal healthcare programs, effective April 19, 2018, for a minimum of fifteen years. In the DEA proceeding, the factual allegations were deemed admitted following administrative default.

The decision explains that mandatory exclusion under the cited federal statute can independently support DEA registration action even when the underlying conviction does not involve controlled substances. It expressly distinguishes that basis from permissive exclusion. This is a new administrative registration decision resting on an older exclusion, rather than a new criminal conviction or a newly starting fifteen-year exclusion. Exclusion screening and controlled-substance credentialing therefore need separate status checks; the October 29 final-order date does not postpone an exclusion that was already effective.

DEA’s order concerning Johann Farley, M.D., revokes registration BF8869628 and denies pending renewal, modification and additional Indiana registration applications. Signed September 21 and published September 29, it takes effect October 29, 2026. The agency found that a June 11, 2024 federal healthcare-fraud guilty plea led to mandatory exclusion from Medicare, Medicaid and all federal healthcare programs for a minimum of twelve years, effective May 20, 2025. The DEA case proceeded to default after the registrant did not continue defending it.

The decision relies on mandatory exclusion as an independent statutory basis for registration action and distinguishes it from permissive exclusion. It also records that the DEA registration had expired September 30, 2025. Neither that expiration nor the earlier program exclusion should be obscured by the future effective date of the final administrative order. For organizations using exclusion and credentialing data, the practical distinction is between an old criminal plea, an already effective exclusion, an expired registration and the newly published final decision. The order does not itself establish later reinstatement or a stay.

DOJ’s October 1 announcement reports an indictment charging Kijuana Evans and Lonnie Griffin with wire-fraud conspiracy, wire fraud and money laundering. According to the indictment, Evans owned TriState Guardian Services, appointed as fiduciary for incapacitated adults by the Oakland County Probate Court. Griffin managed TriState and operated Key to Life, a non-emergency transportation company. Court-appointed guardians and conservators are entrusted to manage personal and financial affairs in their wards’ interests; the charges allege misuse of that position.

The alleged diversions include $87,000 from a ward to buy a transit van used by Griffin’s company, $180,000 from a ward’s home sale, and proceeds of a ward’s lawsuit settlement deposited into the defendants’ account. Those sums concern money belonging to wards and their estates, rather than an announced Medicaid recovery. The defendants are presumed innocent, and the indictment is not evidence of guilt. The case-specific oversight concern is the combination of fiduciary authority, related transportation interests and transactions that require independent authorization and reconciliation.

DOJ reported that Skyler Garman was sentenced to one year of probation for conspiracies involving distribution of misbranded drugs and money laundering, with forfeiture of $180,000 in offense proceeds. Garman admitted 2019–2021 distribution of selective androgen receptor modulators and selective estrogen receptor modulators in violation of federal drug law. He operated Body Science Supplements and associated brands, using internet sales and interstate shipping. The release distinguishes unapproved new drugs and misbranded products from lawful dietary supplements.

The described products bore labels such as not for human consumption while Garman and an associate advised customers about dosing for human performance uses. Body Science and its brands sold more than $2.2 million in products, the large majority described as unapproved and misbranded drugs, producing more than $180,000 in net profit for Garman. The forfeiture amount is not the same as total sales, and an order does not prove collection. The case shows why purchasing and promotion reviews must examine actual use claims and customer advice alongside labels, rather than rely on a research-only disclaimer.

DOJ’s September 28 release reports that Iowa attorney Timothy Mark Anderson was sentenced September 11 to six months in federal prison following an October 30, 2025 guilty plea to a false statement relating to a healthcare matter. The court imposed a $25,000 fine, $184,274.36 in restitution to Iowa Medicaid and two years of supervised release. The release describes his assistance to elderly clients seeking Medicaid-funded nursing-home care and a series of purported luxury-vehicle purchases, gifts to heirs and discounted resales from 2017 through 2022.

The transactions purported to use Iowa’s exemption for one vehicle used to transport the applicant or a household member, but purchasers generally never drove or saw the vehicles. In the detailed example, Anderson took $186,000 for a Rolls-Royce that had recently been damaged and was inoperable, then submitted a valuation he knew was false. The case turns on sham transactions and an inaccurate eligibility representation, not merely ownership of a valuable vehicle. Iowa’s rule should not be imported into Medi-Cal advice, and the restitution order does not prove receipt. Reliable transaction, valuation and actual-use evidence are central to the resulting review.

In Massachusetts, an October 1 release reports an indictment of a defendant identified as John Doe for alleged use of a deceased citizen’s identity to obtain SNAP, MassHealth and an identification card. The charges remain allegations. The release describes a SNAP application file with an unresolved death-match notation before benefits were approved; that particular notation concerns SNAP, rather than proof of an identical processing failure in MassHealth. Prior state convictions described in the release are separate from the pending federal benefit-fraud charges.

The October 2 Kansas release reports a different completed disposition: Simon Flores-Torres received twenty-four months in prison after an aggravated-identity-theft plea. A passport application prompted an investigation that identified use of a person’s identity after that person died in 2015. The release separates $95,811 in Social Security benefits, $97,095 in Medicaid and $24,269 in SNAP, with restitution required by the plea agreement. The two cases support resolving identity discrepancies through applicable program procedures, but must not be merged into a single prosecution, a common loss total or a claim that every pending allegation has been proven.

DOJ’s October 8 release reports a thirty-year sentence for Christopher Neal Mishik, a licensed professional counselor who offered online care to adolescents, young adults and families. The criminal case concerns participation in online groups coordinating child exploitation, including activity during summer 2024. The release identifies both his occupation and the criminal enterprise but does not say the exploited children were his counseling patients. Those facts should remain separate rather than implying that the crime occurred through clinical sessions.

The account of court documents describes social-media targeting and impersonation, with evidence recovered during a November 2025 search of his residence. The sentence is an imposed criminal disposition, not a licensing-board action or an OCR privacy resolution. For healthcare organizations, a proportionate response is to examine relevant workforce safeguarding, credentialing and escalation processes while protecting victim privacy. The source does not justify conclusions about the safety of all telehealth counseling, employer knowledge or a patient relationship that it never establishes.

DOJ’s October 7 announcement reports that Deontae Britton, also known as Deaundre Blount, was sentenced to eighty months in prison and three years of supervised release. The conspiracy involved twenty pharmacies in Maryland, Pennsylvania and Virginia between January and April 2022. The release describes after-hours forced entry, damage to doors and locks, and visits lasting less than two minutes while controlled substances were taken for unlawful distribution. The historical burglary period is distinct from the current sentence date.

The stolen products included opioids and other controlled medications, making physical security and prompt inventory reconciliation connected concerns. The release reports a separate forty-month sentence for William Sherod III and states that Harold Dorman’s case remained pending; Britton’s disposition should not be attributed to every participant. The case supports review of after-hours detection, entry protection and a response that can establish what stock is missing. It does not announce a new universal security deadline or establish that any particular pharmacy control would have prevented every burglary.

DOJ’s October 7 announcement reports the arrest and charge of Jonathan Durocher for attempted sex trafficking of a child. The allegations stem from a June 15 undercover advertisement and communications during a law-enforcement operation around the Boston-area World Cup period. After an initial appearance, he was released on conditions including location monitoring and no unsupervised contact with anyone under eighteen. Those release conditions are distinct from a criminal sentence, and the charge remains an allegation.

The release identifies recent work as a caregiver at a residential home serving adults with developmental disabilities, brain injuries or other daily-living needs. It does not state that residents were victims, that the alleged conduct occurred at work or that the employer participated. That limited occupational connection supports consideration of relevant workforce safeguarding and escalation processes without inventing institutional wrongdoing. The defendant is presumed innocent; the statutory imprisonment range described in the notice depends on conviction and must not be presented as punishment already imposed.